Our mission
Providing custom tailored, high quality preclinical services to prime your drugs for success.
WHY US
We offer expert solutions for optimal preclinical testing
- standardized efficacy evaluation platforms
- long standing expertise in preclinical testing
- humanized precision models
- unique animal models mimicking the complexity of human disease
- over 100 therapeutics successfully tested
- scientific excellence
LATEST NEWS & BLOG

Categories NewsPosted on
The scleroderma model induced by mini osmotic pump released bleomycin integrates comprehensive histopathological and molecular readouts of fibrosis and inflammation, providing a well-established and highly translational in vivo preclinical platform for evaluating novel therapeutics targeting fibrosis.

Categories NewsPosted on
Tg3647 mice develop progressive interstitial lung pathology with pathological findings of arteriole occlusion and right ventricular hypertrophy closely mirroring the human condition of Pulmonary Arterial Hypertension (PAH).

Categories NewsPosted on
The bleomycin-induced IPF mouse model developed in Biomedcode integrates comprehensive histopathological and molecular readouts of inflammation and fibrosis, providing a well-established and highly translational in vivo preclinical platform for evaluating novel therapeutics targeting fibrosis.
PRECLINICAL SERVICES DELIVERED
134
CLIENTS
480
CONTRACTS
195
THERAPEUTICS TESTED
27
COUNTRIES

OUR CLIENTS SAY
"Our company had a pleasant experience of productive collaboration with Biomedcode s.a. in 2015. We would like to especially highlight the high quality of the study protocol preparation and report writing as well as efficient communication with Biomedcode’s CEO. We greatly appreciate your professionalism and looking forward to our future collaboration."
Biopharmaceutical company
Moscow, Russia
"We have several collaborations with Biomedcode, their scientific and efficient experiment schedules made each collaboration accomplished according to plan. From Biomedcode, we obtained convincing study reports and detailed records, which saved a lot of time for us in whole pre-clinical stage. We believe contracting professional works to such a professional and sophisticated group is a wise choice."
"It was a great pleasure working with Biomedcode that exhibited great expertise in preclinical testing and handled all the steps of the study with great professionalism always abiding by the terms of the agreement and always staying in close communication with us making this a very productive collaboration."
Biopharmaceutical company
Shanghai, China
"The authors acknowledge the role of BioMedCode relating to studies involving the human Tg197 TNF transgenic mouse model of polyarthritis in identifying sensitive study designs to optimally address efficacy comparability in this well-establish and characterized disease model"
Biopharmaceutical company
Germany
"…that was a pleasure to work with Biomedcode. Perfect in every aspect: study design, correspondence, preparation of the report, timing, additional discussions and etc. Biomedcode was recommended to us by the other company and after working with them we highly recommend Biomedcode to everyone."
Biopharmaceutical company
Moscow, RussiaClients
Research Funding
Collaborators

Categories PublicationsPosted on
Our new publication in Arthritis Rheumatology presents a new mouse model recapitulating the complexity of human SLE

Categories News, PublicationsPosted on
Exploring the interplay between inflammation and senescence in the context of combination anti-arthritic therapeutic approaches.

Categories News, PublicationsPosted on
Introducing a novel mouse model to explore the role of human RANKL in breast cancer and assemble a preclinical tool for anticancer drug evaluation.

